Bruce H Cohen1, J Russell Geyer2, Douglas C Miller3, John G Curran4, Tianni Zhou5, Emi Holmes6, Sue Ann Ingles6, Ira J Dunkel7, Joanne Hilden8, Roger J Packer9, Ian F Pollack10, Amar Gajjar11, Jonathan L Finlay12. 1. NeuroDevelopmental Science Center and The Department of Pediatrics, Children's Hospital Medical Center of Akron, Ohio and Northeast Ohio Medical University, Rootstown, Ohio. Electronic address: bcohen@chmca.org. 2. Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, Washington. 3. Department of Pathology & Anatomical Sciences, University of Missouri School of Medicine, Columbia, Missouri. 4. Division of Radiology, Phoenix Children's Hospital, Phoenix, Arizona. 5. University of Southern California, Keck School of Medicine, Los Angeles, California; Department of Mathematics and Statistics, California State University, Long Beach, California. 6. University of Southern California, Keck School of Medicine, Los Angeles, California. 7. Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York. 8. Departments of Pediatric Hematology/Oncology/Bone Marrow Transplant, Children's Hospital Colorado and University of Colorado School of Medicine, Denver, Colorado. 9. Center for Neuroscience and Behavioral Medicine, Children's National Medical Center, Washington, DC. 10. Division of Pediatric Neurosurgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania. 11. Department of Oncology, St. Jude Children' Research Hospital, Memphis, Tennessee. 12. Neuro-oncology Program, Division of Hematology, Oncology and BMT, Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio.
Abstract
BACKGROUND: The primary goals of the Children's Cancer Group 99703 study were to assess the feasibility and tolerability of-as well as the response rate to-a novel dose-intensive chemotherapy regimen. METHODS: Between March 1998 and October 2004, 92 eligible patients were enrolled. Following biopsy/resection, patients received three identical cycles of Induction chemotherapy (vincristine, cyclophosphamide, etoposide, and cisplatin) administered every 21-28 days. Patients without tumor progression then received three consolidation cycles of marrow-ablative chemotherapy (thiotepa and carboplatin) followed by autologous hematopoietic cell rescue. RESULTS: The maximum tolerated dose of thiotepa was 10 mg/kg/day × 2 days per cycle. The toxic mortality rate was zero during induction and 2.6% during consolidation. Centrally evaluated response rates to induction and consolidation in evaluable patients with residual tumor were 73.3% and 66.7%, respectively. Disease progression rates on induction and consolidation were 4%. Five-year event-free survival and overall survival were 43.9 ± 5.2% and 63.6 ± 5% respectively. Gross total resection versus less than gross total resection were the only significant outcome comparisons: 5-year maximum tolerated dose and overall survival of 54.4 ± 7% versus 28.9 ± 7% (P = 0.0065) and 75.9 ± 8% versus 48.7 ± 8% (P = 0.0034), respectively. The 5-year maximum tolerated dose for localized (M0) versus metastatic (M1+) medulloblastoma was 67.5 ± 9.5% versus 30 ± 14.5% (P = 0.007). The 5-year maximum tolerated dose and overall survival for desmoplastic medulloblastoma patients versus other medulloblastoma were 78.6 ± 11% versus 50.5 ± 12% (P = 0.038) and 85.7 ± 9.4% versus 60.6 ± 11.6% (P = 0.046), respectively. CONCLUSIONS: This phase I dose-escalation study of marrow-ablative thiotepa regimen determined a maximum tolerated dose that had acceptable toxicity. Overall survival data justify this strategy for current Children's Oncology Group studies.
BACKGROUND: The primary goals of the Children's Cancer Group 99703 study were to assess the feasibility and tolerability of-as well as the response rate to-a novel dose-intensive chemotherapy regimen. METHODS: Between March 1998 and October 2004, 92 eligible patients were enrolled. Following biopsy/resection, patients received three identical cycles of Induction chemotherapy (vincristine, cyclophosphamide, etoposide, and cisplatin) administered every 21-28 days. Patients without tumor progression then received three consolidation cycles of marrow-ablative chemotherapy (thiotepa and carboplatin) followed by autologous hematopoietic cell rescue. RESULTS: The maximum tolerated dose of thiotepa was 10 mg/kg/day × 2 days per cycle. The toxic mortality rate was zero during induction and 2.6% during consolidation. Centrally evaluated response rates to induction and consolidation in evaluable patients with residual tumor were 73.3% and 66.7%, respectively. Disease progression rates on induction and consolidation were 4%. Five-year event-free survival and overall survival were 43.9 ± 5.2% and 63.6 ± 5% respectively. Gross total resection versus less than gross total resection were the only significant outcome comparisons: 5-year maximum tolerated dose and overall survival of 54.4 ± 7% versus 28.9 ± 7% (P = 0.0065) and 75.9 ± 8% versus 48.7 ± 8% (P = 0.0034), respectively. The 5-year maximum tolerated dose for localized (M0) versus metastatic (M1+) medulloblastoma was 67.5 ± 9.5% versus 30 ± 14.5% (P = 0.007). The 5-year maximum tolerated dose and overall survival for desmoplastic medulloblastomapatients versus other medulloblastoma were 78.6 ± 11% versus 50.5 ± 12% (P = 0.038) and 85.7 ± 9.4% versus 60.6 ± 11.6% (P = 0.046), respectively. CONCLUSIONS: This phase I dose-escalation study of marrow-ablative thiotepa regimen determined a maximum tolerated dose that had acceptable toxicity. Overall survival data justify this strategy for current Children's Oncology Group studies.
Authors: André O von Bueren; Katja von Hoff; Torsten Pietsch; Nicolas U Gerber; Monika Warmuth-Metz; Frank Deinlein; Isabella Zwiener; Andreas Faldum; Gudrun Fleischhack; Martin Benesch; Juergen Krauss; Joachim Kuehl; Rolf D Kortmann; Stefan Rutkowski Journal: Neuro Oncol Date: 2011-06 Impact factor: 12.300
Authors: Mark Van Poppel; Paul Klimo; Mariko Dewire; Robert A Sanford; Frederick Boop; Alberto Broniscer; Karen Wright; Amar J Gajjar Journal: J Neurosurg Pediatr Date: 2011-09 Impact factor: 2.375
Authors: A E Evans; R D Jenkin; R Sposto; J A Ortega; C B Wilson; W Wara; I J Ertel; S Kramer; C H Chang; S L Leikin Journal: J Neurosurg Date: 1990-04 Impact factor: 5.115
Authors: Quinn T Ostrom; Peter M de Blank; Carol Kruchko; Claire M Petersen; Peter Liao; Jonathan L Finlay; Duncan S Stearns; Johannes E Wolff; Yingli Wolinsky; John J Letterio; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2015-01 Impact factor: 12.300
Authors: B H Cohen; R J Packer; K R Siegel; L B Rorke; G D'Angio; L N Sutton; D A Bruce; L Schut Journal: Pediatr Neurosurg Date: 1993 Jul-Aug Impact factor: 1.162
Authors: J H Wisoff; J M Boyett; M S Berger; C Brant; H Li; A J Yates; P McGuire-Cullen; P A Turski; L N Sutton; J C Allen; R J Packer; J L Finlay Journal: J Neurosurg Date: 1998-07 Impact factor: 5.115
Authors: J L Finlay; C August; R Packer; R Zimmerman; L Sutton; A Freid; L Rorke; E Bayever; N Kamani; E Kramer Journal: J Neurooncol Date: 1990-12 Impact factor: 4.130
Authors: Erin E Crotty; Sarah E S Leary; J Russell Geyer; James M Olson; Nathan E Millard; Aimee A Sato; Ralph P Ermoian; Bonnie L Cole; Christina M Lockwood; Vera A Paulson; Samuel R Browd; Richard G Ellenbogen; Jason S Hauptman; Amy Lee; Jeffrey G Ojemann; Nicholas A Vitanza Journal: J Neurooncol Date: 2020-06-16 Impact factor: 4.130
Authors: Taryn B Fay-McClymont; Danielle M Ploetz; Don Mabbott; Karin Walsh; Amy Smith; Susan N Chi; Elizabeth Wells; Jennifer Madden; Ashley Margol; Jonathan Finlay; Mark W Kieran; Douglas Strother; Girish Dhall; Roger J Packer; Nicholas K Foreman; E Bouffet; Lucie Lafay-Cousin Journal: J Neurooncol Date: 2017-04-12 Impact factor: 4.130
Authors: Alyssa T Reddy; Douglas R Strother; Alexander R Judkins; Peter C Burger; Ian F Pollack; Mark D Krailo; Allen B Buxton; Chris Williams-Hughes; Maryam Fouladi; Anita Mahajan; Thomas E Merchant; Ben Ho; Claire M Mazewski; Victor A Lewis; Amar Gajjar; Louis-Gilbert Vezina; Timothy N Booth; Kerry W Parsons; Vicky L Poss; Tianni Zhou; Jaclyn A Biegel; Annie Huang Journal: J Clin Oncol Date: 2020-02-27 Impact factor: 44.544
Authors: Eveline Teresa Hidalgo; Matija Snuderl; Cordelia Orillac; Svetlana Kvint; Jonathan Serrano; Peter Wu; Matthias A Karajannis; Sharon L Gardner Journal: Childs Nerv Syst Date: 2019-08-02 Impact factor: 1.475
Authors: C Altshuler; K Haley; G Dhall; L Vasquez; S L Gardner; J Stanek; J L Finlay Journal: Bone Marrow Transplant Date: 2016-03-07 Impact factor: 5.483
Authors: Chantel Cacciotti; Muhammad Ali; Ute Bartels; Jonathan D Wasserman; Erilda Kapllani; Joerg Krueger; Eric Bouffet; Tal Schechter Journal: Childs Nerv Syst Date: 2020-11-18 Impact factor: 1.475